Extramedullary hematopoiesis in cancer.

Jemal, A., Thomas, A., Murray, T. & Thun, M. Cancer statistics, 2002. CA Cancer J. Clin. 52, 23–47 (2002).

doi: 10.3322/canjclin.52.1.23

Nahrendorf, M. Myeloid cell contributions to cardiovascular health and disease. Nat. Med. 24, 711–720 (2018).

doi: 10.1038/s41591-018-0064-0

Oduro, K. A. Jr. et al. Myeloid skewing in murine autoimmune arthritis occurs in hematopoietic stem and primitive progenitor cells. Blood J. Am. Soc. Hematol. 120, 2203–2213 (2012).

Wu, C. et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J. Clin. Invest. 128, 3425–3438 (2018).

doi: 10.1172/JCI97973

Corbeau, I., Jacot, W. & Guiu, S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. Cancers 12, 958 (2020).

doi: 10.3390/cancers12040958

Iwai, N. et al. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Sci. Rep. 10, 1–7 (2020).

doi: 10.1038/s41598-020-75745-8

Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, dju124 (2014).

doi: 10.1093/jnci/dju124

Zhang, Y. et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. Medicine 97, e0144 (2018).

doi: 10.1097/MD.0000000000010144

De Cicco, P., Ercolano, G. & Ianaro, A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. Front. Immunol. 11, 1680 (2020).

doi: 10.3389/fimmu.2020.01680

O’Malley, D. P. Benign extramedullary myeloid proliferations. Mod. Pathol. 20, 405–415 (2007).

doi: 10.1038/modpathol.3800768

Bao, Y. et al. Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review. Cancer Manag. Res. 10, 1461 (2018).

doi: 10.2147/CMAR.S161746

Khalil, S., Ariel Gru, A. & Saavedra, A. P. Cutaneous extramedullary haematopoiesis: Implications in human disease and treatment. Exp. Dermatol. 28, 1201–1209 (2019).

doi: 10.1111/exd.14013

Fan, N., Lavu, S., Hanson, C. A. & Tefferi, A. Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients. Blood Cancer J. 8, 1–4 (2018).

doi: 10.1038/s41408-018-0156-6

Nagai, Y. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24, 801–812 (2006).

doi: 10.1016/j.immuni.2006.04.008

Regan-Komito, D. et al. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nat. Commun. 11, 1–15 (2020).

doi: 10.1038/s41467-019-13853-4

Peters, M. et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6–sIL-6R double transgenic mice. J. Exp. Med. 185, 755–766 (1997).

doi: 10.1084/jem.185.4.755

Khan, K. N. M. et al. Recombinant human interleukin-3 induces extramedullary hematopoiesis at subcutaneous injection sites in cynomolgus monkeys. Toxicol. Pathol. 24, 391–397 (1996).

doi: 10.1177/019262339602400401

Dagdas, S. et al. Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating factor. Acta Haematol. 116, 198–202 (2006).

doi: 10.1159/000094681

Cenariu, D. et al. Extramedullary hematopoiesis of the liver and spleen. J. Clin. Med. 10, 5831 (2021).

doi: 10.3390/jcm10245831

Conor O’keane, J., Wolf, B. C. & Neiman, R. S. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 63, 1539–1543 (1989).

doi: 10.1002/1097-0142(19890415)63:8<1539::AID-CNCR2820630814>3.0.CO;2-5

Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109, 2491–2496 (2012).

doi: 10.1073/pnas.1113744109

Wu, W.-C. et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc. Natl Acad. Sci. USA 111, 4221–4226 (2014).

doi: 10.1073/pnas.1320753111

Lu, I.-N. et al. Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. Nat. Commun. 12, 1–16 (2021).

doi: 10.1038/s41467-021-23995-z

Barisas, D. A. et al. Tumor-derived interleukin-1α and leukemia inhibitory factor promote extramedullary hematopoiesis. PLoS Biol. 21, e3001746 (2023).

doi: 10.1371/journal.pbio.3001746

Koch, C. A., Li, C.-Y., Mesa, R. A. & Tefferi, A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. In Mayo Clinic Proceedings. Elsevier; 2003. pp. 1223–1233.

Blais, M. È., Louis, I. & Perreault, C. T‐cell development: an extrathymic perspective. Immunol. Rev. 209, 103–114 (2006).

doi: 10.1111/j.0105-2896.2006.00341.x

Mitroulis, I., Kalafati, L., Hajishengallis, G. & Chavakis, T. Myelopoiesis in the context of innate immunity. J. Innate Immun. 10, 365–372 (2018).

doi: 10.1159/000489406

Chiba, Y. et al. Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases. Cell. Mol. Life Sci. 75, 1363–1376 (2018).

doi: 10.1007/s00018-017-2724-5

Rosenbauer, F. & Tenen, D. G. Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 7, 105–117 (2007).

doi: 10.1038/nri2024

Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C. & Maki, R. A. The macrophage and B cell-specific transcription factor PU. 1 is related to the ets oncogene. Cell 61, 113–124 (1990).

doi: 10.1016/0092-8674(90)90219-5

Zhang, D.-E. et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc. Natl Acad. Sci. USA 94, 569–574 (1997).

doi: 10.1073/pnas.94.2.569

Tanaka, T. et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80, 353–361 (1995).

doi: 10.1016/0092-8674(95)90418-2

Yamanaka, R. et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein ɛ-deficient mice. Proc. Natl Acad. Sci. USA 94, 13187–13192 (1997).

doi: 10.1073/pnas.94.24.13187

Hock, H. et al. Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 18, 109–120 (2003).

doi: 10.1016/S1074-7613(02)00501-0

Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317 (1996).

doi: 10.1016/S0092-8674(00)81348-3

Hirai, H. et al. C/EBPβ is required for’emergency’granulopoiesis. Nat. Immunol. 7, 732–739 (2006).

doi: 10.1038/ni1354

Lieschke, G. J. et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737–1746 (1994).

doi: 10.1182/blood.V84.6.1737.1737

Basu, S. et al. “Emergency” granulopoiesis in G-CSF–deficient mice in response to Candida albicans infection. Blood J. Am. Soc. Hematol. 95, 3725–3733 (2000).

Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18, 607–618 (2016).

doi: 10.1038/ncb3346

Zhan, Y. & Cheers, C. Haemopoiesis in mice genetically lacking granulocyte–macrophage colony stimulating factor during chronic infection with Mycobacterium avium. Immunol. Cell Biol. 78, 118–123 (2000).

doi: 10.1046/j.1440-1711.2000.00891.x

Seita, J. et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood J. Am. Soc. Hematol. 111, 1903–1912 (2008).

Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).

doi: 10.1038/s41577-019-0210-z

Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C. & Allavena, P. Tumor-associated myeloid cells: diversity and therapeutic targeting. Cell. Mol. Immunol. 18, 566–578 (2021).

doi: 10.1038/s41423-020-00613-4

Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).

doi: 10.1038/s41577-020-00490-y

Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5, eaay6017 (2020).

doi: 10.1126/sciimmunol.aay6017

Condamine, T. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 1, aaf8943–aaf8943 (2016).

doi: 10.1126/sciimmunol.aaf8943

Condamine, T., Mastio, J. & Gabrilovich, D. I. Transcriptional regulation of myeloid‐derived suppressor cells. J. Leukoc. Biol. 98, 913–922 (2015).

doi: 10.1189/jlb.4RI0515-204R

Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174 (2009).

doi: 10.1038/nri2506

Condamine, T. & Gabrilovich, D. I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32, 19–25 (2011).

doi: 10.1016/j.it.2010.10.002

Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity. Blood, J. Am. Soc. Hematol. 111, 4233–4244 (2008).

Waight, J. D., Hu, Q., Miller, A., Liu, S. & Abrams, S. I. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE 6, e27690 (2011).

doi: 10.1371/journal.pone.0027690

Li, W. et al. G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers. Protein Cell 7, 130–140 (2016).

doi: 10.1007/s13238-015-0237-2

Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1–19 (2018).

doi: 10.1038/s41467-018-03600-6

Casbon, A.-J. et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl Acad. Sci. USA 112, E566–E575 (2015).

doi: 10.1073/pnas.1424927112

Stadtmann, A. & Zarbock, A. CXCR2: from bench to bedside. Front. Immunol. 3, 263 (2012).

doi: 10.3389/fimmu.2012.00263

Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693–698 (2020).

doi: 10.1038/s41591-020-0860-1

Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26, 688–692 (2020).

doi: 10.1038/s41591-020-0856-x

Tazawa, H. et al. Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am. J. Pathol. 163, 2221–2232 (2003).

doi: 10.1016/S0002-9440(10)63580-8

Spicer, J. D. et al. Neutrophils promote liver metastasis via mac-1–mediated interactions with circulating tumor cellsneutrophil/tumor cell adhesion promotes metastasis. Cancer Res. 72, 3919–3927 (2012).

doi: 10.1158/0008-5472.CAN-11-2393

Shang, K. et al. Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS ONE 7, e51848 (2012).

doi: 10.1371/journal.pone.0051848

Jamieson, T. et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J. Clin. Investig. 122, 3127–3144 (2012).

doi: 10.1172/JCI61067

Katoh, H. et al. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24, 631–644 (2013).

doi: 10.1016/j.ccr.2013.10.009

Wang, Y., Ding, Y., Guo, N. & Wang, S. MDSCs: key criminals of tumor pre-metastatic niche formation. Front. Immunol. 10, 172 (2019).

doi: 10.3389/fimmu.2019.00172

Li, P. et al. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nat. Immunol. 21, 1444–1455 (2020).

doi: 10.1038/s41590-020-0783-5

Lin, P. et al. Expansion of myeloid immune suppressor cells in Tumor-bearing host directly promotes tumor angiogenesis, tumor growth, and metastasis. Clin. Cancer Res. 13, PL02-02–PL02-02 (2007).

Kowanetz, M. et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+ Ly6C+ granulocytes. Proc. Natl Acad. Sci. USA 107, 21248–21255 (2010).

doi: 10.1073/pnas.1015855107

Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825–831 (2007).

doi: 10.1038/nature06348

Kusmartsev, S. et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 181, 346–353 (2008).

doi: 10.4049/jimmunol.181.1.346

Toh, B. et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 9, e1001162 (2011).

doi: 10.1371/journal.pbio.1001162

Cools-Lartigue, J. et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Investig. 123, 3446–3458 (2013).

doi: 10.1172/JCI67484

Mendelson, A. & Frenette, P. S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. Nat. Med. 20, 833–846 (2014).

doi: 10.1038/nm.3647

Calvi, L. M. & Link, D. C. The hematopoietic stem cell niche in homeostasis and disease. Blood J. Am. Soc. Hematol. 126, 2443–2451 (2015).

Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977–988 (2006).

doi: 10.1016/j.immuni.2006.10.016

Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 481, 457–462 (2012).

doi: 10.1038/nature10783

Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466, 829–834 (2010).

doi: 10.1038/nature09262

Pinho, S. et al. PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J. Exp. Med. 210, 1351–1367 (2013).

doi: 10.1084/jem.20122252

Greenbaum, A. et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495, 227–230 (2013).

doi: 10.1038/nature11926

Zhang, J. et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836–841 (2003).

doi: 10.1038/nature02041

Calvi, L. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841–846 (2003).

doi: 10.1038/nature02040

Ding, L. & Morrison, S. J. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495, 231–235 (2013).

doi: 10.1038/nature11885

Ding, D.-C., Shyu, W.-C. & Lin, S.-Z. Mesenchymal stem cells. Cell Transplant. 20, 5–14 (2011).

doi: 10.3727/096368910X

Kennedy, M. et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 386, 488–493 (1997).

doi: 10.1038/386488a0

Kobayashi, H. et al. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nat. Cell Biol. 12, 1046–1056 (2010).

doi: 10.1038/ncb2108

Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62–66 (1995).

doi: 10.1038/376062a0

Doan, P. L. et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat. Med. 19, 295–304 (2013).

doi: 10.1038/nm.3070

Himburg, H. A. et al. Pleiotrophin regulates the retention and self-renewal of hematopoietic stem cells in the bone marrow vascular niche. Cell Rep. 2, 964–975 (2012).

doi: 10.1016/j.celrep.2012.09.002

Hooper, A. T. et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 4, 263–274 (2009).

doi: 10.1016/j.stem.2009.01.006

Kunisaki, Y. et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502, 637–643 (2013).

doi: 10.1038/nature12612

Méndez-Ferrer, S., Lucas, D., Battista, M. & Frenette, P. S. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 452, 442–447 (2008).

doi: 10.1038/nature06685

Katayama, Y. et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124, 407–421 (2006).

doi: 10.1016/j.cell.2005.10.041

Yamazaki, S. et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147, 1146–1158 (2011).

doi: 10.1016/j.cell.2011.09.053

Yamazaki, S. et al. TGF-β as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood J. Am. Soc. Hematol. 113, 1250–1256 (2009).

Heazlewood, S. Y. et al. Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. Stem Cell Res. 11, 782–792 (2013).

doi: 10.1016/j.scr.2013.05.007

Bruns, I. et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat. Med. 20, 1315–1320 (2014).

doi: 10.1038/nm.3707

Zhao, M. et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat. Med. 20, 1321–1326 (2014).

doi: 10.1038/nm.3706

Olson, T. S. et al. Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. Blood J. Am. Soc. Hematol. 121, 5238–5249 (2013).

Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208, 261–271 (2011).

doi: 10.1084/jem.20101688

Christopher, M. J., Rao, M., Liu, F., Woloszynek, J. R. & Link, D. C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J. Exp. Med. 208, 251–260 (2011).

doi: 10.1084/jem.20101700

Andonegui, G. et al. Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J. Clin. Investig. 119, 1921–1930 (2009).

Day, R. B., Bhattacharya, D., Nagasawa, T. & Link, D. C. Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice. Blood J. Am. Soc. Hematol. 125, 3114–3117 (2015).

Ikushima, Y. M. et al. Prostaglandin E2 regulates murine hematopoietic stem/progenitor cells directly via EP4 receptor and indirectly through mesenchymal progenitor cells. Blood J. Am. Soc. Hematol. 121, 1995–2007 (2013).

Itkin, T., Kaufmann, K. B., Gur-Cohen, S., Ludin, A. & Lapidot, T. Fibroblast growth factor signaling promotes physiological bone remodeling and stem cell self-renewal. Curr. Opin. Hematol. 20, 237–244 (2013).

Decker, M. et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat. Cell Biol. 19, 677–688 (2017).

doi: 10.1038/ncb3530

Dykstra, B., Olthof, S., Schreuder, J., Ritsema, M. & De Haan, G. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J. Exp. Med. 208, 2691–2703 (2011).

doi: 10.1084/jem.20111490

Sudo, K., Ema, H., Morita, Y. & Nakauchi, H. Age-associated characteristics of murine hematopoietic stem cells. J. Exp. Med. 192, 1273–1280 (2000).

doi: 10.1084/jem.192.9.1273

Maryanovich, M. et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. Nat. Med. 24, 782–791 (2018).

doi: 10.1038/s41591-018-0030-x

Ho, Y.-H. et al. Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging. Cell Stem Cell 25, 407–418. e406 (2019).

doi: 10.1016/j.stem.2019.06.007

Mitchell, C. A. et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat. Cell Biol. 25, 30–41 (2023).

doi: 10.1038/s41556-022-01053-0

Bowers, E. & Singer, K. Obesity-induced inflammation: the impact of the hematopoietic stem cell niche. JCI insight 6, e145295 (2021).

doi: 10.1172/jci.insight.145295

Naveiras, O. et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259–263 (2009).

doi: 10.1038/nature08099

Zhu, R.-J., Wu, M.-Q., Li, Z.-J., Zhang, Y. & Liu, K.-Y. Hematopoietic recovery following chemotherapy is improved by BADGE-induced inhibition of adipogenesis. Int. J. Hematol. 97, 58–72 (2013).

doi: 10.1007/s12185-012-1233-4

Mattiucci, D. et al. Bone marrow adipocytes support hematopoietic stem cell survival. J. Cell. Physiol. 233, 1500–1511 (2018).

doi: 10.1002/jcp.26037

Spindler, T. J., Tseng, A. W., Zhou, X. & Adams, G. B. Adipocytic cells augment the support of primitive hematopoietic cells in vitro but have no effect in the bone marrow niche under homeostatic conditions. Stem Cells Dev. 23, 434–441 (2014).

doi: 10.1089/scd.2013.0227

Corre, J. et al. Human bone marrow adipocytes support complete myeloid and lymphoid differentiation from human CD34+ cells. Br. J. Haematol. 127, 344–347 (2004).

doi: 10.1111/j.1365-2141.2004.05198.x

Liu, L.-F., Shen, W.-J., Ueno, M., Patel, S. & Kraemer, F. B. Characterization of age-related gene expression profiling in bone marrow and epididymal adipocytes. BMC Genomics 12, 1–18 (2011).

doi: 10.1186/1471-2164-12-S5-S1

Miggitsch, C. et al. Human bone marrow adipocytes display distinct immune regulatory properties. EBioMedicine 46, 387–398 (2019).

doi: 10.1016/j.ebiom.2019.07.023

Inra, C. N. et al. A perisinusoidal niche for extramedullary haematopoiesis in the spleen. Nature 527, 466–471 (2015).

doi: 10.1038/nature15530

Mendt, M. & Cardier, J. E. Role of SDF-1 (CXCL12) in regulating hematopoietic stem and progenitor cells traffic into the liver during extramedullary hematopoiesis induced by G-CSF, AMD3100 and PHZ. Cytokine 76, 214–221 (2015).

doi: 10.1016/j.cyto.2015.05.004

Kogame, T. et al. Presence of SCF/CXCL 12 double‐positive large blast‐like cells at the site of cutaneous extramedullary haematopoiesis. J. Eur. Acad. Dermatol. Venereol. 32, e465–e466 (2018).

doi: 10.1111/jdv.15068

Oda, A. et al. Niche-induced extramedullary hematopoiesis in the spleen is regulated by the transcription factor Tlx1. Sci. Rep. 8, 1–16 (2018).

doi: 10.1038/s41598-018-26693-x

Broxmeyer, H. E. et al. Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M. Immunity 16, 815–825 (2002).

doi: 10.1016/S1074-7613(02)00319-9

Lee, J. H., Wang, C. & Kim, C. H. FoxP3+ regulatory T cells restrain splenic extramedullary myelopoiesis via suppression of hemopoietic cytokine-producing T cells. J. Immunol. 183, 6377–6386 (2009).

doi: 10.4049/jimmunol.0901268

Chow, A. et al. CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat. Med. 19, 429–436 (2013).

doi: 10.1038/nm.3057

Liu, M. et al. Macrophages support splenic erythropoiesis in 4T1 tumor-bearing mice. PLoS ONE 10, e0121921 (2015).

doi: 10.1371/journal.pone.0121921

Dutta, P. et al. Macrophages retain hematopoietic stem cells in the spleen via VCAM-1. J. Exp. Med. 212, 497–512 (2015).

doi: 10.1084/jem.20141642

Ulyanova, T., Phelps, S. R. & Papayannopoulou, T. The macrophage contribution to stress erythropoiesis: when less is enough. Blood J. Am. Soc. Hematol. 128, 1756–1765 (2016).

Huang, E. et al. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63, 225–233 (1990).

doi: 10.1016/0092-8674(90)90303-V

Fong, Y. & Blumgart, L. H. Surgery Of The Liver And Biliary Tract (WB Saunders, 2000).

Brannan, C. et al. Developmental abnormalities in Steel17H mice result from a splicing defect in the steel factor cytoplasmic tail. Genes Dev. 6, 1832–1842 (1992).

doi: 10.1101/gad.6.10.1832

Russell, E. S. Hereditary anemias of the mouse: a review for geneticists. Adv. Genet. 20, 357–459 (1979).

doi: 10.1016/S0065-2660(08)60549-0

Kapur, R. et al. Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood J. Am. Soc. Hematol. 91, 879–889 (1998).

Tajima, Y. et al. Consequences of exclusive expression in vivo of Kit-ligand lacking the major proteolytic cleavage site. Proc. Natl Acad. Sci. USA 95, 11903–11908 (1998).

doi: 10.1073/pnas.95.20.11903

Qiu, F. et al. Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. EMBO J. 7, 1003–1011 (1988).

doi: 10.1002/j.1460-2075.1988.tb02907.x

Yarden, Y. et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6, 3341–3351 (1987).

doi: 10.1002/j.1460-2075.1987.tb02655.x

Lev, S., Blechman, J. M., Givol, D. & Yarden, Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit. Rev. Oncog. 5, 141–168 (1994).

doi: 10.1615/CritRevOncog.v5.i2-3.30

Kapur, R., Chandra, S., Cooper, R., McCarthy, J. & Williams, D. A. Role of p38 and ERK MAP kinase in proliferation of erythroid progenitors in response to stimulation by soluble and membrane isoforms of stem cell factor. Blood J. Am. Soc. Hematol. 100, 1287–1293 (2002).

Kurosawa, K. et al. Immobilized anti-KIT monoclonal antibody induces ligand-independent dimerization and activation of Steel factor receptor: biologic similarity with membrane-bound form of Steel factor rather than its soluble form. Blood 87, 2235–2243 (1996).

doi: 10.1182/blood.V87.6.2235.bloodjournal8762235

Thorén, L. A. et al. Kit regulates maintenance of quiescent hematopoietic stem cells. J. Immunol. 180, 2045–2053 (2008).

doi: 10.4049/jimmunol.180.4.2045

Wu, H., Klingmüller, U., Acurio, A., Hsiao, J. G. & Lodish, H. F. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. Proc. Natl Acad. Sci. USA 94, 1806–1810 (1997).

doi: 10.1073/pnas.94.5.1806

Jahn, T. et al. Direct interaction between Kit and the interleukin-7 receptor. Blood J. Am. Soc. Hematol. 110, 1840–1847 (2007).

Zhu, M. et al. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene 26, 6386–6395 (2007).

doi: 10.1038/sj.onc.1210464

Kim, C. H. & Broxmeyer, H. E. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell–derived factor-1, steel factor, and the bone marrow environment. Blood J. Am. Soc. Hematol. 91, 100–110 (1998).

Brightman, F. A., Leahy, D. E., Searle, G. E. & Thomas, S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab. Dispos. 34, 94–101 (2006).

doi: 10.1124/dmd.105.004838

Bachelerie, F. et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66, 1 (2014).

doi: 10.1124/pr.113.007724

Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121–127 (2000).

doi: 10.1016/S1074-7613(00)80165-X

Oberlin, E. et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833–835 (1996).

doi: 10.1038/382833a0

Bleul, C. C. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829–833 (1996).

doi: 10.1038/382829a0

Balabanian, K. et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280, 35760–35766 (2005).

doi: 10.1074/jbc.M508234200

Burns, J. M. et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201–2213 (2006).

doi: 10.1084/jem.20052144

Cruz-Orengo, L. et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J. Exp. Med. 208, 327–339 (2011).

doi: 10.1084/jem.20102010

Ma, Q. et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc. Natl Acad. Sci. USA 95, 9448–9453 (1998).

doi: 10.1073/pnas.95.16.9448

Gerrits, H. et al. Early postnatal lethality and cardiovascular defects in CXCR7‐deficient mice. Genesis 46, 235–245 (2008).

doi: 10.1002/dvg.20387

Sierro, F. et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl Acad. Sci. USA 104, 14759–14764 (2007).

doi: 10.1073/pnas.0702229104

Rubin, J. B. Chemokine signaling in cancer: one hump or two? In Seminars in Cancer Biology. Elsevier; 2009. pp. 116–122.

Busillo, J. M. & Benovic, J. L. Regulation of CXCR4 signaling. Biochim. Biophys. Acta (BBA)-Biomembr. 1768, 952–963 (2007).

doi: 10.1016/j.bbamem.2006.11.002

Soldevila, G. et al. Impaired chemokine‐induced migration during T‐cell development in the absence of Jak 3. Immunology 112, 191–200 (2004).

doi: 10.1111/j.1365-2567.2004.01863.x

Zhang, X.-F., Wang, J.-F., Matczak, E., Proper, J. & Groopman, J. E. Janus kinase 2 is involved in stromal cell–derived factor-1α–induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood J. Am. Soc. Hematol. 97, 3342–3348 (2001).

Vila‐Coro, A. J. et al. The chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13, 1699–1710 (1999).

doi: 10.1096/fasebj.13.13.1699

Moriguchi, M. et al. CXCL12 signaling is independent of Jak2 and Jak3. J. Biol. Chem. 280, 17408–17414 (2005).

doi: 10.1074/jbc.M414219200

Thelen, M. Dancing to the tune of chemokines. Nat. Immunol. 2, 129–134 (2001).

doi: 10.1038/84224

Sun, Y., Cheng, Z., Ma, L. & Pei, G. β-Arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J. Biol. Chem. 277, 49212–49219 (2002).

doi: 10.1074/jbc.M207294200

Shukla, A. K., Xiao, K. & Lefkowitz, R. J. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 36, 457–469 (2011).

doi: 10.1016/j.tibs.2011.06.003

Bendall, L. J. & Bradstock, K. F. G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 25, 355–367 (2014).

doi: 10.1016/j.cytogfr.2014.07.011

Fukunaga, R., Ishizaka-Ikeda, E. & Nagata, S. Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. J. Biol. Chem. 265, 14008–14015 (1990).

doi: 10.1016/S0021-9258(18)77449-8

Dong, F. et al. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. J. Immunol. 161, 6503–6509 (1998).

doi: 10.4049/jimmunol.161.12.6503

Cornish, A. L., Campbell, I. K., McKenzie, B. S., Chatfield, S. & Wicks, I. P. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 554–559 (2009).

doi: 10.1038/nrrheum.2009.178

Kawakami, M. et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76, 1962–1964 (1990).

doi: 10.1182/blood.V76.10.1962.1962

Cebon, J., Layton, J. E., Maher, D. & Morstyn, G. Endogenous haemopoietic growth factors in neutropenia and infection. Br. J. Haematol. 86, 265–274 (1994).

doi: 10.1111/j.1365-2141.1994.tb04725.x

Liu, F., Wu, H. Y., Wesselschmidt, R., Kornaga, T. & Link, D. C. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor–deficient mice. Immunity 5, 491–501 (1996).

doi: 10.1016/S1074-7613(00)80504-X

Tamura, M. et al. Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF). Biochem. Biophys. Res. Commun. 142, 454–460 (1987).

doi: 10.1016/0006-291X(87)90296-8

Dinarello, C. A. Overview of the IL‐1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8–27 (2018).

doi: 10.1111/imr.12621

Towne, J. E. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J. Biol. Chem. 286, 42594–42602 (2011).

doi: 10.1074/jbc.M111.267922

Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).

doi: 10.1016/S0140-6736(17)32247-X

Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

doi: 10.1056/NEJMoa1707914

Pyrillou, K., Burzynski, L. C. & Clarke, M. C. Alternative pathways of IL-1 activation, and its role in health and disease. Front. Immunol. 11, 613170 (2020).

doi: 10.3389/fimmu.2020.613170

Kim, B. et al. The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front. Immunol. 4, 391 (2013).

doi: 10.3389/fimmu.2013.00391

Malik, A. & Kanneganti, T. D. Function and regulation of IL‐1α in inflammatory diseases and cancer. Immunol. Rev. 281, 124–137 (2018).

doi: 10.1111/imr.12615

Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol. Cell 44, 265–278 (2011).

doi: 10.1016/j.molcel.2011.07.037

Werman, A. et al. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc. Natl Acad. Sci. USA 101, 2434–2439 (2004).

doi: 10.1073/pnas.0308705101

Nicola, N. A. & Babon, J. J. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26, 533–544 (2015).

doi: 10.1016/j.cytogfr.2015.07.001

Metcalf, D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 21, 5–14 (2003).

doi: 10.1634/stemcells.21-1-5

Houben, E., Hellings, N., Broux, B. & Oncostatin, M. an underestimated player in the central nervous system. Front. Immunol. 10, 1165 (2019).

doi: 10.3389/fimmu.2019.01165

Stahl, N. et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components. Science 263, 92–95 (1994).

doi: 10.1126/science.8272873

Rodig, S. J. et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93, 373–383 (1998).

doi: 10.1016/S0092-8674(00)81166-6

Takahashi, Y. et al. Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway. Mol. Endocrinol. 22, 1673–1681 (2008).

doi: 10.1210/me.2008-0058

Chung, B. M. et al. Jak2 and Tyk2 are necessary for lineage-specific differentiation, but not for the maintenance of self-renewal of mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 351, 682–688 (2006).

doi: 10.1016/j.bbrc.2006.10.081

Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1–20 (2003).

doi: 10.1042/bj20030407

Fahmi, A. et al. p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cell. Signal. 25, 898–909 (2013).

doi: 10.1016/j.cellsig.2012.12.008

Oh, H. et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J. Biol. Chem. 273, 9703–9710 (1998).

doi: 10.1074/jbc.273.16.9703

Niwa, H., Burdon, T., Chambers, I. & Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 12, 2048–2060 (1998).

doi: 10.1101/gad.12.13.2048

Paling, N. R., Wheadon, H., Bone, H. K. & Welham, M. J. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J. Biol. Chem. 279, 48063–48070 (2004).

doi: 10.1074/jbc.M406467200

Meloche, S., Vella, F. D., Voisin, L., Ang, S.-L. & Saba-El-Leil, M. Erk2 signaling and early embryo stem cell self-renewal. Cell Cycle 3, 239–241 (2004).

doi: 10.4161/cc.3.3.674

Burdon, T., Stracey, C., Chambers, I., Nichols, J. & Smith, A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Dev. Biol. 210, 30–43 (1999).

doi: 10.1006/dbio.1999.9265

Stewart, C. L. et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359, 76–79 (1992).

doi: 10.1038/359076a0

Giess, R., Tanasescu, I., Steck, T. & Sendtner, M. Leukaemia inhibitory factor gene mutations in infertile women. Mol. Hum. Reprod. 5, 581–586 (1999).

doi: 10.1093/molehr/5.6.581

Charnock-Jones, D., Sharkey, A., Fenwick, P. & Smith, S. Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. Reproduction 101, 421–426 (1994).

doi: 10.1530/jrf.0.1010421

Metcalf, D. & Gearing, D. Fatal syndrome in mice engrafted with cells producing high levels of the leukemia inhibitory factor. Proc. Natl Acad. Sci. USA 86, 5948–5952 (1989).

doi: 10.1073/pnas.86.15.5948

Walker, E. C. et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Investig. 120, 582–592 (2010).

doi: 10.1172/JCI40568

Deverman, B. E. & Patterson, P. H. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J. Neurosci. 32, 2100–2109 (2012).

doi: 10.1523/JNEUROSCI.3803-11.2012

Yoshida, T., Satoh, M., Nakagaito, Y., Kuno, H. & Takeuchi, M. Cytokines affecting survival and differentiation of an astrocyte progenitor cell line. Dev. Brain Res. 76, 147–150 (1993).

doi: 10.1016/0165-3806(93)90132-T

Bauer, S. & Patterson, P. H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J. Neurosci. 26, 12089–12099 (2006).

doi: 10.1523/JNEUROSCI.3047-06.2006

Barnard, W., Bower, J., Brown, M., Murphy, M. & Austin, L. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses lif mRNA. J. Neurol. Sci. 123, 108–113 (1994).

doi: 10.1016/0022-510X(94)90211-9

Austin, L. & Burgess, A. Stimulation of myoblast proliferation in culture by leukaemia inhibitory factor and other cytokines. J. Neurol. Sci. 101, 193–197 (1991).

doi: 10.1016/0022-510X(91)90045-9

Wu, L. et al. HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells. Oncotarget 6, 4406 (2015).

doi: 10.18632/oncotarget.3017

Richards, C. D. The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm. 2013, 512103 (2013).

doi: 10.1155/2013/512103

Metcalfe, S. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun. 12, 157–168 (2011).

doi: 10.1038/gene.2011.9

Albiero, M. et al. Diabetes-associated myelopoiesis drives stem cell mobilopathy through an OSM-p66Shc signaling pathway. Diabetes 68, 1303–1314 (2019).

doi: 10.2337/db19-0080

Langdon, C., Leith, J., Richards, C. D. & Smith, F. Oncostatin M stimulates monocyte chemoattractant protein‐1‐and interleukin‐1‐induced matrix metalloproteinase‐1 production by human synovial fibroblasts in vitro. Arthritis Rheum. 40, 2139–2146 (1997).

doi: 10.1002/art.1780401207

Hui, W., Bell, M. & Carroll, G. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann. Rheum. Dis. 56, 184–187 (1997).

doi: 10.1136/ard.56.3.184

Cawston, T. et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum. 41, 1760–1771 (1998).

doi: 10.1002/1529-0131(199810)41:10<1760::AID-ART8>3.0.CO;2-M

West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017).

doi: 10.1038/nm.4307

Wang, X. & Lin, Y. Tumor necrosis factor and cancer, buddies or foes? 1. Acta Pharmacol. Sin. 29, 1275–1288 (2008).

doi: 10.1111/j.1745-7254.2008.00889.x

Cheng, X., Shen, Y. & Li, R. Targeting TNF: a therapeutic strategy for Alzheimer’s disease. Drug Discov. today 19, 1822–1827 (2014).

doi: 10.1016/j.drudis.2014.06.029

Al Sayed, M. F. et al. T-cell–secreted TNFα induces emergency myelopoiesis and myeloid-derived suppressor cell differentiation in cancer. Cancer Res. 79, 346–359 (2019).

doi: 10.1158/0008-5472.CAN-17-3026

Veenstra, M. & Ransohoff, R. M. Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J. Neuroimmunol. 246, 1–9 (2012).

doi: 10.1016/j.jneuroim.2012.02.016

Ahuja, S. K., Özçelik, T., Milatovitch, A., Francke, U. & Murphy, P. M. Molecular evolution of the human interleukin–8 receptor gene cluster. Nat. Genet. 2, 31–36 (1992).

doi: 10.1038/ng0992-31

Knall, C. et al. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J. Biol. Chem. 271, 2832–2838 (1996).

doi: 10.1074/jbc.271.5.2832

Murdoch, C. & Finn, A. Chemokine receptors and their role in inflammation and infectious diseases. Blood J. Am. Soc. Hematol. 95, 3032–3043 (2000).

Luan, J. et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukoc. Biol. 62, 588–597 (1997).

doi: 10.1002/jlb.62.5.588

Moore, B. B. et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 154, 1503–1512 (1999).

doi: 10.1016/S0002-9440(10)65404-1

Karpova, D. et al. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. J. Clin. Investig. 129, 2745–2759 (2019).

doi: 10.1172/JCI124738

Sendo, S., Saegusa, J. & Morinobu, A. Myeloid-derived suppressor cells in non-neoplastic inflamed organs. Inflamm. Regen. 38, 1–11 (2018).

doi: 10.1186/s41232-018-0076-7

Coudereau, R. et al. Emergence of immunosuppressive LOX‐1+ PMN‐MDSC in septic shock and severe COVID‐19 patients with acute respiratory distress syndrome. J. Leukoc. Biol. 111, 489–496 (2022).

doi: 10.1002/JLB.4COVBCR0321-129R

De Zuani, M. et al. Human myeloid‐derived suppressor cell expansion during sepsis is revealed by unsupervised clustering of flow cytometric data. Eur. J. Immunol. 51, 1785–1791 (2021).

doi: 10.1002/eji.202049141

Kurkó, J. et al. Identification of myeloid-derived suppressor cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet. Disord. 15, 1–7 (2014).

doi: 10.1186/1471-2474-15-281

Zhang, R. et al. Dextran sulphate sodium increases splenic Gr1+ CD11b+ cells which accelerate recovery from colitis following intravenous transplantation. Clin. Exp. Immunol. 164, 417–427 (2011).

doi: 10.1111/j.1365-2249.2011.04374.x

Ioannou, M. et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J. Immunol. 188, 1136–1146 (2012).

doi: 10.4049/jimmunol.1101816

Orphanidou-Vlachou, E., Tziakouri-Shiakalli, C. & Georgiades, C. S. Extramedullary hemopoiesis. In Seminars in Ultrasound, CT and MRI. Elsevier; 2014. pp. 255–262.

Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. Nature 541, 321–330 (2017).

doi: 10.1038/nature21349

Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat. Immunol. 21, 835–847 (2020).

doi: 10.1038/s41590-020-0728-z

Gong, Y., Klein Wolterink, R. G., Wang, J., Bos, G. M. & Germeraad, W. T. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J. Hematol. Oncol. 14, 1–35 (2021).

doi: 10.1186/s13045-021-01083-5

Yu, S. et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J. Hematol. Oncol. 10, 1–13 (2017).

doi: 10.1186/s13045-017-0444-9

García-Martínez, E. et al. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology 7, e1433982 (2018).

doi: 10.1080/2162402X.2018.1433982

Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood J. Am. Soc. Hematol. 127, 3321–3330 (2016).

Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).

doi: 10.1016/j.cell.2021.09.020

Extramedullary hematopoiesis in cancer.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Derek A G Barisas (DAG)

Kyunghee Choi (K)

Classifications MeSH